39 results on '"Schally, Andrew V."'
Search Results
2. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia
3. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins
4. LHRH Antagonist Cetrorelix Reduces Prostate Size and Gene Expression of Proinflammatory Cytokines and Growth Factors in A Rat Model of Benign Prostatic Hyperplasia
5. Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) in Benign Prostatic Hyperplasia (BPH) As Potential Molecular Targets for Therapy With LHRH Antagonist Cetrorelix†
6. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Proliferation of Human Benign Prostatic Hyperplasia Cells
7. Dose-Dependent Growth Inhibition In Vivo of PC-3 Prostate Cancer With a Reduction in Tumoral Growth Factors After Therapy With GHRH Antagonist MZ-J-7-138
8. The Combination of Antagonists of LHRH With Antagonists of GHRH Improves Inhibition of Androgen Sensitive MDA-PCa-2b and LuCaP-35 Prostate Cancers
9. Inhibition of Human Experimental Prostate Cancers by a Targeted Cytotoxic Luteinizing Hormone-Releasing Hormone Analog AN-207
10. Antagonists of Growth Hormone Releasing Hormone (GHRH) and of Bombesin/Gastrin Releasing Peptide (BN/GRP) Suppress the Expression of VEGF, bFGF, and Receptors of the EGF/HER Family in PC-3 and DU-145 Human Androgen-Independent Prostate Cancers
11. Growth hormone‐releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan‐induced chronic prostatitis.
12. Growth hormone‐releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
13. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
14. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
15. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
16. Peptide analogs in the therapy of prostate cancer.
17. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
18. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
19. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
20. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
21. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: Internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells.
22. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
23. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
24. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the dunning R-3327H rat prostate cancer model.
25. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
26. Histological changes in dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
27. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
28. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
29. Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer.
30. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
31. Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone.
32. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: Comparison with other hormonal agents.
33. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
34. Treatment of prostatic carcinoma with D-Trp-6-LH-RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations.
35. Treatment of advanced prostatic carcinoma with D-trp-6-LH-RH.
36. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of dunning R-3327H prostate cancer model.
37. Endogenous phosphorylation in dunning prostate tumors of rats treated with LH-RH analogues.
38. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
39. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.